Caisson Establishes Partnership with CordenPharma


AUSTIN, Texas & OKLAHOMA CITY–Caisson Biotech, LLC (Caisson), a leader in half-life extension and drug delivery, today announced it has established a global manufacturing partnership with CordenPharma International (CordenPharma), a full-service Contract Development & Manufacturing Organization (CDMO) manufacturing APIs and Drug Products through a network of cGMP facilities across Europe and the US.

Caisson has demonstrated successful technology transfer and cGMP scale-up with its corporate pharmaceutical partners utilizing its patented heparosan-based half-life extension and drug delivery platform, HEPtune®, and will establish similar capabilities with CordenPharma in order to supply licensing partners with HEPtune drug conjugate material. As a manufacturer of the HEPtune® technology, CordenPharma will bring experience and expertise in process development and manufacture of complex carbohydrates, including carbohydrate-based polymers and glyco-conjugates, which are an integral component of its Peptides, Lipids & Carbohydrates technology platform offering.

Subscribe to get the latest news